OTCMKTS:IMNPQ

Immune Pharmaceuticals Competitors

$0.17
+0.03 (+17.86 %)
(As of 04/14/2021 03:59 PM ET)
Add
Compare
Today's Range
$0.12
Now: $0.17
$0.17
50-Day Range
$0.01
MA: $0.02
$0.10
52-Week Range
$0.00
Now: $0.17
$0.18
Volume10.84 million shs
Average Volume3.73 million shs
Market Capitalization$3.47 million
P/E RatioN/A
Dividend YieldN/A
Beta0.69

Competitors

Immune Pharmaceuticals (OTCMKTS:IMNPQ) Vs. PKPH, TOWTF, TRLPF, NXEN, WHCA, and ACUR

Should you be buying IMNPQ stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Immune Pharmaceuticals, including Peak Pharmaceuticals (PKPH), Tower One Wireless (TOWTF), Acerus Pharmaceuticals (TRLPF), Nexien BioPharma (NXEN), Williston (WHCA), and Acura Pharmaceuticals (ACUR).

Immune Pharmaceuticals (OTCMKTS:IMNPQ) and Peak Pharmaceuticals (OTCMKTS:PKPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Earnings & Valuation

This table compares Immune Pharmaceuticals and Peak Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immune PharmaceuticalsN/AN/AN/AN/AN/A
Peak PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Immune Pharmaceuticals and Peak Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immune Pharmaceuticals0000N/A
Peak Pharmaceuticals0000N/A

Profitability

This table compares Immune Pharmaceuticals and Peak Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Immune PharmaceuticalsN/AN/AN/A
Peak PharmaceuticalsN/AN/AN/A

Risk & Volatility

Immune Pharmaceuticals has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Peak Pharmaceuticals has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.

Summary

Immune Pharmaceuticals beats Peak Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Immune Pharmaceuticals (OTCMKTS:IMNPQ) and Tower One Wireless (OTCMKTS:TOWTF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Earnings & Valuation

This table compares Immune Pharmaceuticals and Tower One Wireless' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immune PharmaceuticalsN/AN/AN/AN/AN/A
Tower One Wireless$4.08 million2.64$-3,750,000.00N/AN/A

Immune Pharmaceuticals has higher earnings, but lower revenue than Tower One Wireless.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Immune Pharmaceuticals and Tower One Wireless, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immune Pharmaceuticals0000N/A
Tower One Wireless0000N/A

Profitability

This table compares Immune Pharmaceuticals and Tower One Wireless' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Immune PharmaceuticalsN/AN/AN/A
Tower One WirelessN/AN/A-39.36%

Risk & Volatility

Immune Pharmaceuticals has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Tower One Wireless has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500.

Summary

Immune Pharmaceuticals beats Tower One Wireless on 2 of the 3 factors compared between the two stocks.

Acerus Pharmaceuticals (OTCMKTS:TRLPF) and Immune Pharmaceuticals (OTCMKTS:IMNPQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

0.0% of Acerus Pharmaceuticals shares are owned by institutional investors. 3.9% of Immune Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for Acerus Pharmaceuticals and Immune Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acerus Pharmaceuticals0000N/A
Immune Pharmaceuticals0000N/A

Profitability

This table compares Acerus Pharmaceuticals and Immune Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Acerus Pharmaceuticals-254.66%-346.72%-94.54%
Immune PharmaceuticalsN/AN/AN/A

Volatility and Risk

Acerus Pharmaceuticals has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500. Comparatively, Immune Pharmaceuticals has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.

Earnings and Valuation

This table compares Acerus Pharmaceuticals and Immune Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acerus Pharmaceuticals$7.38 million1.43$-18,790,000.00N/AN/A
Immune PharmaceuticalsN/AN/AN/AN/AN/A

Immune Pharmaceuticals has lower revenue, but higher earnings than Acerus Pharmaceuticals.

Summary

Immune Pharmaceuticals beats Acerus Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Nexien BioPharma (OTCMKTS:NXEN) and Immune Pharmaceuticals (OTCMKTS:IMNPQ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Nexien BioPharma and Immune Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nexien BioPharmaN/AN/A$-2,670,000.00N/AN/A
Immune PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Nexien BioPharma and Immune Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nexien BioPharmaN/A-16,049.80%-6,651.95%
Immune PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Nexien BioPharma and Immune Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nexien BioPharma0000N/A
Immune Pharmaceuticals0000N/A

Risk and Volatility

Nexien BioPharma has a beta of -701.47, suggesting that its share price is 70,247% less volatile than the S&P 500. Comparatively, Immune Pharmaceuticals has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.

Summary

Immune Pharmaceuticals beats Nexien BioPharma on 3 of the 3 factors compared between the two stocks.

Immune Pharmaceuticals (OTCMKTS:IMNPQ) and Williston (OTCMKTS:WHCA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Immune Pharmaceuticals and Williston, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immune Pharmaceuticals0000N/A
Williston0000N/A

Earnings and Valuation

This table compares Immune Pharmaceuticals and Williston's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immune PharmaceuticalsN/AN/AN/AN/AN/A
WillistonN/AN/AN/AN/AN/A

Risk & Volatility

Immune Pharmaceuticals has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Williston has a beta of -1.09, suggesting that its stock price is 209% less volatile than the S&P 500.

Profitability

This table compares Immune Pharmaceuticals and Williston's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Immune PharmaceuticalsN/AN/AN/A
WillistonN/AN/AN/A

Summary

Immune Pharmaceuticals beats Williston on 1 of the 1 factors compared between the two stocks.

Immune Pharmaceuticals (OTCMKTS:IMNPQ) and Acura Pharmaceuticals (OTCMKTS:ACUR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Immune Pharmaceuticals and Acura Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immune Pharmaceuticals0000N/A
Acura Pharmaceuticals0000N/A

Earnings and Valuation

This table compares Immune Pharmaceuticals and Acura Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immune PharmaceuticalsN/AN/AN/AN/AN/A
Acura Pharmaceuticals$2.66 million2.67N/AN/AN/A

Risk & Volatility

Immune Pharmaceuticals has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Acura Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

Profitability

This table compares Immune Pharmaceuticals and Acura Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Immune PharmaceuticalsN/AN/AN/A
Acura Pharmaceuticals-19.89%-1.36%-34.83%

Summary

Immune Pharmaceuticals beats Acura Pharmaceuticals on 3 of the 5 factors compared between the two stocks.

Ad MicroCapWatch
Stock to Keep an Eye On
Strong management, innovative products – this company won’t be under the radar for long

Immune Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Peak Pharmaceuticals logo
PKPH
Peak Pharmaceuticals
0.7$0.15+1.7%$11.36 millionN/A0.00
Tower One Wireless logo
TOWTF
Tower One Wireless
0.0$0.12+4.5%$11.25 million$4.08 million-1.28Increase in Short Interest
Acerus Pharmaceuticals logo
TRLPF
Acerus Pharmaceuticals
0.5$0.04+0.0%$10.53 million$7.38 million0.00High Trading Volume
Gap Up
Nexien BioPharma logo
NXEN
Nexien BioPharma
0.0$0.14+23.4%$9.87 millionN/A0.00Gap Up
Williston logo
WHCA
Williston
0.0$0.70+0.0%$9.51 millionN/A0.00
Acura Pharmaceuticals logo
ACUR
Acura Pharmaceuticals
0.6$0.32+17.9%$8.38 million$2.66 million-10.71Gap Up
ULUR
ULURU
0.3$0.28+0.0%$8.17 millionN/A0.00Decrease in Short Interest
GlobeImmune logo
GBIM
GlobeImmune
0.5$1.53+17.4%$7.25 millionN/A0.00Gap Down
Parnell Pharmaceuticals logo
PARNF
Parnell Pharmaceuticals
0.5$0.36+0.0%$7.20 millionN/A0.00
Pivotal Therapeutics logo
PVTTF
Pivotal Therapeutics
0.6$0.08+0.0%$7.15 millionN/A0.00News Coverage
Wellness Center USA logo
WCUI
Wellness Center USA
0.5$0.06+6.7%$6.39 million$30,000.000.00Gap Down
KAYS
Kaya
0.7$0.47+8.1%$6.23 million$1.01 million0.00Gap Up
International Stem Cell logo
ISCO
International Stem Cell
0.8$0.72+4.2%$5.65 million$9.47 million0.00
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.23+4.8%$5.19 million$3.48 million-1.92News Coverage
BCTXF
BriaCell Therapeutics
0.0N/AN/A$4.59 millionN/A-0.01
FutureWorld logo
FWDG
FutureWorld
0.5$0.00+16.7%$4.56 millionN/A0.00Gap Down
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.11+4.3%$4.49 million$3.65 million0.00Decrease in Short Interest
AMBS
Amarantus BioScience
0.0$0.01+1.8%$4.13 millionN/A0.00Increase in Short Interest
AKRXQ
Akorn
0.1$0.03+0.0%$3.60 million$682.43 million-0.01
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01+1.3%$3.45 millionN/A0.00Increase in Short Interest
News Coverage
RSPI
RespireRx Pharmaceuticals
0.5$0.04+5.6%$3.00 millionN/A-0.09
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
NSPX
Inspyr Therapeutics
0.5$0.02+1.3%$2.34 millionN/A0.00Gap Down
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02+2.6%$2.22 million$20,000.00-0.98
VVUSQ
VIVUS
0.6$0.12+0.0%$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.48+6.2%$2.01 millionN/A0.00
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01+5.6%$1.95 million$2 million0.00High Trading Volume
Gap Down
WWHC
W World
0.8$6.09+0.0%$1.80 millionN/A0.00Increase in Short Interest
News Coverage
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.03+21.6%$1.70 million$530,000.000.00Gap Down
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.51+5.9%$1.69 millionN/A0.00
Cardax logo
CDXI
Cardax
0.0$2.00+5.0%$1.67 million$710,000.000.00
MLNTQ
Melinta Therapeutics
0.2$0.11+0.0%$1.51 million$96.43 million0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03+0.4%$1.31 million$8.73 million0.00Gap Up
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.25+79.4%$1.12 millionN/A-2.76Decrease in Short Interest
News Coverage
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04+19.7%$1.11 millionN/A0.00Gap Up
AOXG
Aoxing Pharmaceutical
0.5$0.02+10.4%$1.05 millionN/A0.00
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.21+4.8%$1.03 millionN/A0.00Decrease in Short Interest
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07+2.1%$970,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
SPHS
Sophiris Bio
0.1$0.03+0.4%$963,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01+12.9%$928,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
ATRX
Adhera Therapeutics
0.0$0.08+0.0%$872,000.00$250,000.000.00
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01+125.0%$772,000.00N/A0.00
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.02+36.3%$749,000.00N/A0.00News Coverage
Gap Up
PXYN
Praxsyn
0.6$0.00+20.0%$678,000.00N/A0.00Increase in Short Interest
SKVI
Skinvisible
0.7$0.15+0.0%$671,000.00$40,000.000.00
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05+0.0%$572,000.00$1.90 million0.00
TRPXD
Therapix Biosciences
0.0$9.15+1.0%$458,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.17+0.0%$436,000.00N/A0.00
HSTC
HST Global
0.8$0.07+0.0%$378,000.00N/A0.00
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01+17.6%$374,000.00N/A0.00Increase in Short Interest
Gap Down
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.